Eddie Cliff
@eddiecliff.bsky.social
haematology registrar PMCC & RMH | research affiliate, PORTAL, BWH/HMS | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer
Reposted by Eddie Cliff
For me, this hits close to home. We’ve seen what happened with lomustine and the impact on brain tumor patients when a life-saving therapy becomes inaccessible. These aren’t abstract policy issues — they have real consequences for people.
@eddiecliff.bsky.social @mskcancercenter.bsky.social
@eddiecliff.bsky.social @mskcancercenter.bsky.social
November 21, 2025 at 3:59 PM
For me, this hits close to home. We’ve seen what happened with lomustine and the impact on brain tumor patients when a life-saving therapy becomes inaccessible. These aren’t abstract policy issues — they have real consequences for people.
@eddiecliff.bsky.social @mskcancercenter.bsky.social
@eddiecliff.bsky.social @mskcancercenter.bsky.social
Just out at JNCI, we review 20 years of RCTs in myeloma for lessons in drug development.
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
November 9, 2025 at 10:08 PM
Just out at JNCI, we review 20 years of RCTs in myeloma for lessons in drug development.
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
Surprisingly, head-to-head trials were as likely to be successful as add-on trials.
academic.oup.com/jnci/advance... #mmsm #myeloma
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
November 4, 2025 at 9:53 AM
Finally out - our real world study of 740 patients with large B-cell lymphoma receiving polatuzumab vedotin shows higher response rates and PFS for patients with non-GCB LBCL than those with GCB disease, by Hans algorithm.
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Thanks David Russler-Germain + collabs
aacrjournals.org/clincancerre...
Reposted by Eddie Cliff
The US Food and Drug Administration accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
ja.ma/3Kz6WnV
ja.ma/3Kz6WnV
October 9, 2025 at 12:00 PM
The US Food and Drug Administration accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
ja.ma/3Kz6WnV
ja.ma/3Kz6WnV
Reposted by Eddie Cliff
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
October 27, 2025 at 4:30 PM
RW pola outcomes by Hans COO @eddiecliff.bsky.social
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
- 740 pts, 59% R/R
- R/R: ORR 60% non-GC (vs 36% GC), PFS better in non-GC
- 1L: no diff in outcomes
Hans useful in choosing pola in R/R. In 1L, supports POLARIX that pola mitigates worse non-GC outcomes. #lymsm
aacrjournals.org/clincancerre...
Reposted by Eddie Cliff
The urgency is real—but the “Most Favored Nation” drug pricing policy is unlikely to deliver lasting reform. In @jama.com, @eddiecliff.bsky.social and I propose accelerating and strengthening Medicare drug price negotiation to align prices with value.
🔗 jamanetwork.com/journals/jam...
🔗 jamanetwork.com/journals/jam...
August 2, 2025 at 2:01 PM
The urgency is real—but the “Most Favored Nation” drug pricing policy is unlikely to deliver lasting reform. In @jama.com, @eddiecliff.bsky.social and I propose accelerating and strengthening Medicare drug price negotiation to align prices with value.
🔗 jamanetwork.com/journals/jam...
🔗 jamanetwork.com/journals/jam...
Reposted by Eddie Cliff
Viewpoint: The reintroduction of the most favored nation pricing policy aims to curb high US drug prices but faces legal and operational challenges.
ja.ma/4lXJcYs
ja.ma/4lXJcYs
July 28, 2025 at 4:18 PM
Viewpoint: The reintroduction of the most favored nation pricing policy aims to curb high US drug prices but faces legal and operational challenges.
ja.ma/4lXJcYs
ja.ma/4lXJcYs
Just out @jama.com, led by Ian Liu we review 10 years of nononcology accelerated approvals
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
July 15, 2025 at 1:05 AM
Just out @jama.com, led by Ian Liu we review 10 years of nononcology accelerated approvals
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
12/50 vaccines
10 nonmalignant haem
11 neurology
5 nonvaccine ID
>60% conversions to regular approval based on surrogate endpoints
jamanetwork.com/journals/jam... @portalresearch.org @akesselheim.bsky.social
Reposted by Eddie Cliff
The US FDA accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
https://ja.ma/4lRpuge
https://ja.ma/4lRpuge
July 14, 2025 at 3:45 PM
The US FDA accelerated approval pathway spans many nononcologic diseases, especially nonmalignant hematology and neurology, with 25% for infectious disease vaccines.
https://ja.ma/4lRpuge
https://ja.ma/4lRpuge
Reposted by Eddie Cliff
Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25
June 13, 2025 at 1:36 PM
Currently at #EHA2025: @broeckelmann.bsky.social presenting our recent @thelancethaem.bsky.social commission on adverse events, starting with our paper (with @biostatgirl.bsky.social) on advancing the measurement & dissemination of AE data HT @eddiecliff.bsky.social #EHA25
Reposted by Eddie Cliff
🔍Presenting at #ASCO25 as a #poster and now LIVE on our website
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
June 2, 2025 at 2:47 PM
🔍Presenting at #ASCO25 as a #poster and now LIVE on our website
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
Predictors of withdrawal of anticancer drug indications granted accelerated approval: a retrospective cohort study
Read the whole paper here: www.thelancet.com/journals/ecl...
#TheLancet #Oncology #OncologyResearch #MedSky
Reposted by Eddie Cliff
Announcing the 1st paper of @thelancethaem.bsky.social Commission on Adverse Events, with Drs. @biostatgirl.bsky.social & Thanarajasingam.
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
May 29, 2025 at 5:45 PM
Announcing the 1st paper of @thelancethaem.bsky.social Commission on Adverse Events, with Drs. @biostatgirl.bsky.social & Thanarajasingam.
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
We review advances in measuring & reporting newly-described AEs and provide analytic & AE visualization tools for dissemination.
buff.ly/SchRHhq
Thread ⬇️🧵
What steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting & identification?
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
May 31, 2025 at 11:15 AM
What steps can trialists, regulators, journals, editors, reviewers, sponsors & academics take to improve toxicity reporting & identification?
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
👇 check out this figure from our @thelancethaem.bsky.social adverse event commission
www.thelancet.com/journals/lan... @broeckelmann.bsky.social
Reposted by Eddie Cliff
For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...
May 30, 2025 at 10:30 AM
For the third (open access) paper, I was humbled to coordinate an international author panel to comprehensively summarize challenges, lessons learned and outline future strategies for tolerability assessment with novel, targeted therapeutic approaches: doi.org/10.1016/S235...
The latest in a trio of meta-analyses by Tobias, David & Kai just out at Molecular Therapy, on non-relapse mortality after bispecific antibodies in lymphoma & myeloma.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
April 13, 2025 at 12:27 AM
The latest in a trio of meta-analyses by Tobias, David & Kai just out at Molecular Therapy, on non-relapse mortality after bispecific antibodies in lymphoma & myeloma.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
>70% of non-relapse deaths are due to infection.
Need to prioritise measurement, reporting, prophylaxis, early intervention.
Just out @jama.com
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
April 6, 2025 at 9:34 AM
Just out @jama.com
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
Led by Dr Hwang we show when oncology drugs withdrawn due to negative trials are still accessible off-abel, prescribing plummets anyway
Romidepsin a notable exception, unsurprising to lymphoma docs who use it in TFH lymphomas
jamanetwork.com/journals/jam... @portalresearch.org
Delighted Piers Blombery joined us to discuss CAR transgenic T-cell lymphoproliferative neoplasms & all things post-CAR-T malignancies on Blood Cancer Talks, with a side helping of molecular haematology. We discuss Piers' recent NEJM paper plus recent MSKCC case w transgene integration into TP53.
March 26, 2025 at 10:02 PM
Delighted Piers Blombery joined us to discuss CAR transgenic T-cell lymphoproliferative neoplasms & all things post-CAR-T malignancies on Blood Cancer Talks, with a side helping of molecular haematology. We discuss Piers' recent NEJM paper plus recent MSKCC case w transgene integration into TP53.
A real honour to have Dr Hagop Kantarjian, M.D. on the podcast to talk all things CML, including the recent ASCEMBL trial - a really enjoyable hour packed full of wisdom!
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
Blood Cancer Talks
Education Podcast · 57 Episodes · Updated Semimonthly
podcasts.apple.com
February 16, 2025 at 8:55 PM
A real honour to have Dr Hagop Kantarjian, M.D. on the podcast to talk all things CML, including the recent ASCEMBL trial - a really enjoyable hour packed full of wisdom!
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
podcasts.apple.com/us/podcast/b...
Check out Blood Cancer Talks on your favourite podcast platform. #leusm #leukemia #cml
Helpful review on ctDNA in aggressive B-cell lymphomas just out in @jama.com oncology jamanetwork.com/journals/jam... #lymsm #lymphoma
Circulating Tumor DNA as Measurable Residual Disease in Aggressive B-Cell Lymphoma
This narrative review explores how the identification of measurable residual disease through methods of detecting circulating tumor DNA contributes to outcomes for B-cell lymphomas.
jamanetwork.com
February 16, 2025 at 5:48 AM
Helpful review on ctDNA in aggressive B-cell lymphomas just out in @jama.com oncology jamanetwork.com/journals/jam... #lymsm #lymphoma
Enticing data for axi-cel in high risk upfront DLBCL in ZUMA-12 3 year followup @BloodJournal
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
February 15, 2025 at 5:35 AM
Enticing data for axi-cel in high risk upfront DLBCL in ZUMA-12 3 year followup @BloodJournal
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
75% 3-year progression free survival
ashpublications.org/blood/articl...
Randomised ZUMA-23 data eagerly awaited
#lymsm #lymphoma
Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma
Key Points. Despite having relatively favorable disease kinetics, patients with relapsed/refractory BL who receive CAR T-cells have poor outcomes.Future tr
ashpublications.org
February 15, 2025 at 5:13 AM
Disappointing outcomes for CAR T cells in 31 patients with relapsed/refractory Burkitt lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
Tricky disease to treat. Perhaps combo of chemo and bispecific might offer better long term control
ashpublications.org/blood/articl... #lymsm #lymphoma
SYMPATICO trial - RCT of venetoclax + ibrutinib vs ibr+placebo in R/R mantle cell lymphoma just out in Lancet Oncology
www.sciencedirect.com/science/arti... #lymphoma #lymsm
www.sciencedirect.com/science/arti... #lymphoma #lymsm
February 11, 2025 at 1:10 AM
SYMPATICO trial - RCT of venetoclax + ibrutinib vs ibr+placebo in R/R mantle cell lymphoma just out in Lancet Oncology
www.sciencedirect.com/science/arti... #lymphoma #lymsm
www.sciencedirect.com/science/arti... #lymphoma #lymsm
Updated European guideline on Burkitt lymphoma just out in Lancet Haem - www.thelancet.com/journals/lan... #lymsm #lymphoma #burkitt
Diagnosis and treatment of Burkitt lymphoma in adults: clinical practice guidelines from ERN-EuroBloodNet
Burkitt lymphoma is a rare lymphoma entity that represents less than 5% of adult lymphomas.
Although prognosis has improved with dose-dense therapy, Burkitt lymphoma remains
an area of clinical and bi...
www.thelancet.com
February 11, 2025 at 12:58 AM
Updated European guideline on Burkitt lymphoma just out in Lancet Haem - www.thelancet.com/journals/lan... #lymsm #lymphoma #burkitt
Reposted by Eddie Cliff
New piece led by Anushka Bhaskar @portalresearch.org in STAT First Opinion on protecting public health agencies from damaging political interference -- even the threat of which can greatly affect people's behavior: www.statnews.com/2025/01/31/p...
How to protect HHS, FDA, NIH, and other health agencies from political interference
When politicians subordinate scientific institutions to electoral interests, they undermine immediate public health efforts and inflict lasting damage on institutional credibility.
www.statnews.com
January 31, 2025 at 2:27 PM
New piece led by Anushka Bhaskar @portalresearch.org in STAT First Opinion on protecting public health agencies from damaging political interference -- even the threat of which can greatly affect people's behavior: www.statnews.com/2025/01/31/p...
Reposted by Eddie Cliff
The new administration's FDA -- threat or opportunity for public health? A piece in Health Affairs Forefront with @akesselheim.bsky.social
www.healthaffairs.org/content/fore...
www.healthaffairs.org/content/fore...
Will The New Administration’s FDA Be A Threat Or An Opportunity For The Public's Health? | Health Affairs Forefront
As various reform ideas are proposed, the organized medical and scientific community will need to work with the new leadership at the FDA to promote positive change–and oppose initiatives that undermine the agency, its workforce, and its mission.
www.healthaffairs.org
December 17, 2024 at 10:36 PM
The new administration's FDA -- threat or opportunity for public health? A piece in Health Affairs Forefront with @akesselheim.bsky.social
www.healthaffairs.org/content/fore...
www.healthaffairs.org/content/fore...